申请人:Tel HaShomer Medical Research Infrastructure and Services Ltd.
公开号:US10022382B2
公开(公告)日:2018-07-17
Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
本发明提供了能够抑制 RNA 聚合酶 I 活性的新型化合物,及其在治疗受 RNA 聚合酶 I 调节的疾病或失调(最好是自身免疫性疾病,如多发性硬化症和增殖性疾病)中的用途。
RNA POLYMERASE I INHIBITORS AND USES THEREOF
申请人:TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE
AND SERVICES LTD.
公开号:EP3074391A1
公开(公告)日:2016-10-05
US9688697B2
申请人:——
公开号:US9688697B2
公开(公告)日:2017-06-27
[EN] RNA POLYMERASE I INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ARN POLYMÉRASE I ET LEURS UTILISATIONS
申请人:TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD
公开号:WO2015079411A1
公开(公告)日:2015-06-04
Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases or disorders.